Effects of Growth Hormone on Growth, Insulin Resistance and Related Hormones (Ghrelin, Leptin and Adiponectin) in Turner Syndrome

Background:Concomitant evaluation of the metabolic and growth-promoting effects of growth hormone (GH) therapy in Turner syndrome (TS) may be used in the prediction of the growth response to GH therapy. Aim: To evaluate the metabolic effects of GH therapy in TS and correlation with the short-term gr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hormone research 2007-01, Vol.68 (1), p.1-7
Hauptverfasser: Darendeliler, Feyza, Aycan, Zehra, Cetinkaya, Ergun, Vidilisan, Sadi, Bas, Firdevs, Bideci, Aysun, Demirel, Fatma, Darcan, Sukran, Buyukgebiz, Atilla, Yildiz, Metin, Berberoglu, Merih, Arslanoglu, Ilknur, Bundak, Ruveyde
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 7
container_issue 1
container_start_page 1
container_title Hormone research
container_volume 68
creator Darendeliler, Feyza
Aycan, Zehra
Cetinkaya, Ergun
Vidilisan, Sadi
Bas, Firdevs
Bideci, Aysun
Demirel, Fatma
Darcan, Sukran
Buyukgebiz, Atilla
Yildiz, Metin
Berberoglu, Merih
Arslanoglu, Ilknur
Bundak, Ruveyde
description Background:Concomitant evaluation of the metabolic and growth-promoting effects of growth hormone (GH) therapy in Turner syndrome (TS) may be used in the prediction of the growth response to GH therapy. Aim: To evaluate the metabolic effects of GH therapy in TS and correlation with the short-term growth response. Patients: 24 prepubertal children with TS, aged 9.4 ± 2.6 years were followed for auxology and IGF-I, IGFBP-3, leptin, ghrelin, adiponectin, lipids and OGTT results in a prospective multicenter study. Intervention: GH (Genotropin®) in a dose of 50 µg/kg/day for 1 year. Results: Height standard deviation score (SDS) increased from –3.9 ± 1.5 to –3.5 ± 1.4 (p = 0.000) on therapy. BMI did not change. IGF-I SDS increased from –2.3 ± 0.4 to –1.6 ± 1.1 at 3 and 6 months (p = 0.001) and decreased thereafter. Serum leptin decreased significantly from 2.3 ± 3.9 to 1.7 ± 5.3 ng/ml (p = 0.022) at 3 months and increased afterwards. Serum ghrelin decreased from 1.2 ± 0.8 to 0.9 ± 0.4 ng/ml (p = 0.005) with no change in adiponectin. Basal and stimulated insulin levels also increased significantly. Δ height SDS over 1 year showed a significant correlation with Δ IGF-I 0–3 months (r = 0.450, p = 0.027). Conclusion: IGF-I may be considered as a marker of growth response in TS at short term. Leptin shows a decrease at short term but does not have a correlation with growth response. The decrease in ghrelin in face of unchanged weight seems to be associated with increase in IGF-I and insulin levels. The unchanged adiponectin levels in spite of an increase in insulin levels indicates that adiponectin is mainly affected by weight, not insulin.
doi_str_mv 10.1159/000098440
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1159_000098440</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2837639511</sourcerecordid><originalsourceid>FETCH-LOGICAL-c261t-a9fb251b184d324a7ac78cf2341e1debbca2cdf372bb560fe15e8da16d9a96133</originalsourceid><addsrcrecordid>eNpd0VFLHDEQAOAglSrqQ5-FEiiIgmczyW42-yiip3AgqH1essmkrt1Nrskuxcf-c3PceYIhkEzyzTAwhHwDdgFQ1j9ZXrUqCrZD9kFKMeOKyy_bO6g9cpTSy4oJVdVQfSV7UHFWKFHtk__XzqEZEw2OzmP4Nz7T2xCH4JEGv3k5p3c-TX3n6QOmLo3aG6Ta2xz2ekT7npHo6fw5YobndIHLMSes1KXtlvnX5PiM5renKXqM9PHV2xgGPCS7TvcJjzbnAfl1c_10dTtb3M_vri4XM8MljDNdu5aX0IIqrOCFrrSplHFcFIBgsW2N5sY6UfG2LSVzCCUqq0HaWtcShDggJ-u6yxj-TpjGZuiSwb7XHsOUmopJJnlRZvjjE3wJueXcWwNciLwFU1mdrZWJIaWIrlnGbtDxtQHWrAbTbAeT7fdNxakd0H7IzRgyOF6DPzr-xrgF6_Q363uQ2w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1233233308</pqid></control><display><type>article</type><title>Effects of Growth Hormone on Growth, Insulin Resistance and Related Hormones (Ghrelin, Leptin and Adiponectin) in Turner Syndrome</title><source>Karger e-journals Complete Collection</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Darendeliler, Feyza ; Aycan, Zehra ; Cetinkaya, Ergun ; Vidilisan, Sadi ; Bas, Firdevs ; Bideci, Aysun ; Demirel, Fatma ; Darcan, Sukran ; Buyukgebiz, Atilla ; Yildiz, Metin ; Berberoglu, Merih ; Arslanoglu, Ilknur ; Bundak, Ruveyde</creator><creatorcontrib>Darendeliler, Feyza ; Aycan, Zehra ; Cetinkaya, Ergun ; Vidilisan, Sadi ; Bas, Firdevs ; Bideci, Aysun ; Demirel, Fatma ; Darcan, Sukran ; Buyukgebiz, Atilla ; Yildiz, Metin ; Berberoglu, Merih ; Arslanoglu, Ilknur ; Bundak, Ruveyde</creatorcontrib><description>Background:Concomitant evaluation of the metabolic and growth-promoting effects of growth hormone (GH) therapy in Turner syndrome (TS) may be used in the prediction of the growth response to GH therapy. Aim: To evaluate the metabolic effects of GH therapy in TS and correlation with the short-term growth response. Patients: 24 prepubertal children with TS, aged 9.4 ± 2.6 years were followed for auxology and IGF-I, IGFBP-3, leptin, ghrelin, adiponectin, lipids and OGTT results in a prospective multicenter study. Intervention: GH (Genotropin®) in a dose of 50 µg/kg/day for 1 year. Results: Height standard deviation score (SDS) increased from –3.9 ± 1.5 to –3.5 ± 1.4 (p = 0.000) on therapy. BMI did not change. IGF-I SDS increased from –2.3 ± 0.4 to –1.6 ± 1.1 at 3 and 6 months (p = 0.001) and decreased thereafter. Serum leptin decreased significantly from 2.3 ± 3.9 to 1.7 ± 5.3 ng/ml (p = 0.022) at 3 months and increased afterwards. Serum ghrelin decreased from 1.2 ± 0.8 to 0.9 ± 0.4 ng/ml (p = 0.005) with no change in adiponectin. Basal and stimulated insulin levels also increased significantly. Δ height SDS over 1 year showed a significant correlation with Δ IGF-I 0–3 months (r = 0.450, p = 0.027). Conclusion: IGF-I may be considered as a marker of growth response in TS at short term. Leptin shows a decrease at short term but does not have a correlation with growth response. The decrease in ghrelin in face of unchanged weight seems to be associated with increase in IGF-I and insulin levels. The unchanged adiponectin levels in spite of an increase in insulin levels indicates that adiponectin is mainly affected by weight, not insulin.</description><identifier>ISSN: 1663-2818</identifier><identifier>EISSN: 1663-2826</identifier><identifier>EISSN: 1423-0046</identifier><identifier>DOI: 10.1159/000098440</identifier><identifier>PMID: 17204837</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Adiponectin - blood ; Child ; Child, Preschool ; Cholesterol - blood ; Female ; Ghrelin ; Growth - drug effects ; Human Growth Hormone - pharmacology ; Human Growth Hormone - therapeutic use ; Humans ; Insulin Resistance ; Leptin - blood ; Original Paper ; Peptide Hormones - blood ; Peptide Hormones - drug effects ; Triglycerides - blood ; Turner Syndrome - blood ; Turner Syndrome - drug therapy ; Turner Syndrome - physiopathology</subject><ispartof>Hormone research, 2007-01, Vol.68 (1), p.1-7</ispartof><rights>2007 S. Karger AG, Basel</rights><rights>Copyright 2007 S. Karger AG, Basel.</rights><rights>Copyright (c) 2007 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c261t-a9fb251b184d324a7ac78cf2341e1debbca2cdf372bb560fe15e8da16d9a96133</citedby><cites>FETCH-LOGICAL-c261t-a9fb251b184d324a7ac78cf2341e1debbca2cdf372bb560fe15e8da16d9a96133</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,2430,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17204837$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Darendeliler, Feyza</creatorcontrib><creatorcontrib>Aycan, Zehra</creatorcontrib><creatorcontrib>Cetinkaya, Ergun</creatorcontrib><creatorcontrib>Vidilisan, Sadi</creatorcontrib><creatorcontrib>Bas, Firdevs</creatorcontrib><creatorcontrib>Bideci, Aysun</creatorcontrib><creatorcontrib>Demirel, Fatma</creatorcontrib><creatorcontrib>Darcan, Sukran</creatorcontrib><creatorcontrib>Buyukgebiz, Atilla</creatorcontrib><creatorcontrib>Yildiz, Metin</creatorcontrib><creatorcontrib>Berberoglu, Merih</creatorcontrib><creatorcontrib>Arslanoglu, Ilknur</creatorcontrib><creatorcontrib>Bundak, Ruveyde</creatorcontrib><title>Effects of Growth Hormone on Growth, Insulin Resistance and Related Hormones (Ghrelin, Leptin and Adiponectin) in Turner Syndrome</title><title>Hormone research</title><addtitle>Horm Res Paediatr</addtitle><description>Background:Concomitant evaluation of the metabolic and growth-promoting effects of growth hormone (GH) therapy in Turner syndrome (TS) may be used in the prediction of the growth response to GH therapy. Aim: To evaluate the metabolic effects of GH therapy in TS and correlation with the short-term growth response. Patients: 24 prepubertal children with TS, aged 9.4 ± 2.6 years were followed for auxology and IGF-I, IGFBP-3, leptin, ghrelin, adiponectin, lipids and OGTT results in a prospective multicenter study. Intervention: GH (Genotropin®) in a dose of 50 µg/kg/day for 1 year. Results: Height standard deviation score (SDS) increased from –3.9 ± 1.5 to –3.5 ± 1.4 (p = 0.000) on therapy. BMI did not change. IGF-I SDS increased from –2.3 ± 0.4 to –1.6 ± 1.1 at 3 and 6 months (p = 0.001) and decreased thereafter. Serum leptin decreased significantly from 2.3 ± 3.9 to 1.7 ± 5.3 ng/ml (p = 0.022) at 3 months and increased afterwards. Serum ghrelin decreased from 1.2 ± 0.8 to 0.9 ± 0.4 ng/ml (p = 0.005) with no change in adiponectin. Basal and stimulated insulin levels also increased significantly. Δ height SDS over 1 year showed a significant correlation with Δ IGF-I 0–3 months (r = 0.450, p = 0.027). Conclusion: IGF-I may be considered as a marker of growth response in TS at short term. Leptin shows a decrease at short term but does not have a correlation with growth response. The decrease in ghrelin in face of unchanged weight seems to be associated with increase in IGF-I and insulin levels. The unchanged adiponectin levels in spite of an increase in insulin levels indicates that adiponectin is mainly affected by weight, not insulin.</description><subject>Adiponectin - blood</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Cholesterol - blood</subject><subject>Female</subject><subject>Ghrelin</subject><subject>Growth - drug effects</subject><subject>Human Growth Hormone - pharmacology</subject><subject>Human Growth Hormone - therapeutic use</subject><subject>Humans</subject><subject>Insulin Resistance</subject><subject>Leptin - blood</subject><subject>Original Paper</subject><subject>Peptide Hormones - blood</subject><subject>Peptide Hormones - drug effects</subject><subject>Triglycerides - blood</subject><subject>Turner Syndrome - blood</subject><subject>Turner Syndrome - drug therapy</subject><subject>Turner Syndrome - physiopathology</subject><issn>1663-2818</issn><issn>1663-2826</issn><issn>1423-0046</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpd0VFLHDEQAOAglSrqQ5-FEiiIgmczyW42-yiip3AgqH1essmkrt1Nrskuxcf-c3PceYIhkEzyzTAwhHwDdgFQ1j9ZXrUqCrZD9kFKMeOKyy_bO6g9cpTSy4oJVdVQfSV7UHFWKFHtk__XzqEZEw2OzmP4Nz7T2xCH4JEGv3k5p3c-TX3n6QOmLo3aG6Ta2xz2ekT7npHo6fw5YobndIHLMSes1KXtlvnX5PiM5renKXqM9PHV2xgGPCS7TvcJjzbnAfl1c_10dTtb3M_vri4XM8MljDNdu5aX0IIqrOCFrrSplHFcFIBgsW2N5sY6UfG2LSVzCCUqq0HaWtcShDggJ-u6yxj-TpjGZuiSwb7XHsOUmopJJnlRZvjjE3wJueXcWwNciLwFU1mdrZWJIaWIrlnGbtDxtQHWrAbTbAeT7fdNxakd0H7IzRgyOF6DPzr-xrgF6_Q363uQ2w</recordid><startdate>20070101</startdate><enddate>20070101</enddate><creator>Darendeliler, Feyza</creator><creator>Aycan, Zehra</creator><creator>Cetinkaya, Ergun</creator><creator>Vidilisan, Sadi</creator><creator>Bas, Firdevs</creator><creator>Bideci, Aysun</creator><creator>Demirel, Fatma</creator><creator>Darcan, Sukran</creator><creator>Buyukgebiz, Atilla</creator><creator>Yildiz, Metin</creator><creator>Berberoglu, Merih</creator><creator>Arslanoglu, Ilknur</creator><creator>Bundak, Ruveyde</creator><general>S. Karger AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20070101</creationdate><title>Effects of Growth Hormone on Growth, Insulin Resistance and Related Hormones (Ghrelin, Leptin and Adiponectin) in Turner Syndrome</title><author>Darendeliler, Feyza ; Aycan, Zehra ; Cetinkaya, Ergun ; Vidilisan, Sadi ; Bas, Firdevs ; Bideci, Aysun ; Demirel, Fatma ; Darcan, Sukran ; Buyukgebiz, Atilla ; Yildiz, Metin ; Berberoglu, Merih ; Arslanoglu, Ilknur ; Bundak, Ruveyde</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c261t-a9fb251b184d324a7ac78cf2341e1debbca2cdf372bb560fe15e8da16d9a96133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adiponectin - blood</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Cholesterol - blood</topic><topic>Female</topic><topic>Ghrelin</topic><topic>Growth - drug effects</topic><topic>Human Growth Hormone - pharmacology</topic><topic>Human Growth Hormone - therapeutic use</topic><topic>Humans</topic><topic>Insulin Resistance</topic><topic>Leptin - blood</topic><topic>Original Paper</topic><topic>Peptide Hormones - blood</topic><topic>Peptide Hormones - drug effects</topic><topic>Triglycerides - blood</topic><topic>Turner Syndrome - blood</topic><topic>Turner Syndrome - drug therapy</topic><topic>Turner Syndrome - physiopathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Darendeliler, Feyza</creatorcontrib><creatorcontrib>Aycan, Zehra</creatorcontrib><creatorcontrib>Cetinkaya, Ergun</creatorcontrib><creatorcontrib>Vidilisan, Sadi</creatorcontrib><creatorcontrib>Bas, Firdevs</creatorcontrib><creatorcontrib>Bideci, Aysun</creatorcontrib><creatorcontrib>Demirel, Fatma</creatorcontrib><creatorcontrib>Darcan, Sukran</creatorcontrib><creatorcontrib>Buyukgebiz, Atilla</creatorcontrib><creatorcontrib>Yildiz, Metin</creatorcontrib><creatorcontrib>Berberoglu, Merih</creatorcontrib><creatorcontrib>Arslanoglu, Ilknur</creatorcontrib><creatorcontrib>Bundak, Ruveyde</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Toxicology Abstracts</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Family Health Database (Proquest)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Hormone research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Darendeliler, Feyza</au><au>Aycan, Zehra</au><au>Cetinkaya, Ergun</au><au>Vidilisan, Sadi</au><au>Bas, Firdevs</au><au>Bideci, Aysun</au><au>Demirel, Fatma</au><au>Darcan, Sukran</au><au>Buyukgebiz, Atilla</au><au>Yildiz, Metin</au><au>Berberoglu, Merih</au><au>Arslanoglu, Ilknur</au><au>Bundak, Ruveyde</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of Growth Hormone on Growth, Insulin Resistance and Related Hormones (Ghrelin, Leptin and Adiponectin) in Turner Syndrome</atitle><jtitle>Hormone research</jtitle><addtitle>Horm Res Paediatr</addtitle><date>2007-01-01</date><risdate>2007</risdate><volume>68</volume><issue>1</issue><spage>1</spage><epage>7</epage><pages>1-7</pages><issn>1663-2818</issn><eissn>1663-2826</eissn><eissn>1423-0046</eissn><abstract>Background:Concomitant evaluation of the metabolic and growth-promoting effects of growth hormone (GH) therapy in Turner syndrome (TS) may be used in the prediction of the growth response to GH therapy. Aim: To evaluate the metabolic effects of GH therapy in TS and correlation with the short-term growth response. Patients: 24 prepubertal children with TS, aged 9.4 ± 2.6 years were followed for auxology and IGF-I, IGFBP-3, leptin, ghrelin, adiponectin, lipids and OGTT results in a prospective multicenter study. Intervention: GH (Genotropin®) in a dose of 50 µg/kg/day for 1 year. Results: Height standard deviation score (SDS) increased from –3.9 ± 1.5 to –3.5 ± 1.4 (p = 0.000) on therapy. BMI did not change. IGF-I SDS increased from –2.3 ± 0.4 to –1.6 ± 1.1 at 3 and 6 months (p = 0.001) and decreased thereafter. Serum leptin decreased significantly from 2.3 ± 3.9 to 1.7 ± 5.3 ng/ml (p = 0.022) at 3 months and increased afterwards. Serum ghrelin decreased from 1.2 ± 0.8 to 0.9 ± 0.4 ng/ml (p = 0.005) with no change in adiponectin. Basal and stimulated insulin levels also increased significantly. Δ height SDS over 1 year showed a significant correlation with Δ IGF-I 0–3 months (r = 0.450, p = 0.027). Conclusion: IGF-I may be considered as a marker of growth response in TS at short term. Leptin shows a decrease at short term but does not have a correlation with growth response. The decrease in ghrelin in face of unchanged weight seems to be associated with increase in IGF-I and insulin levels. The unchanged adiponectin levels in spite of an increase in insulin levels indicates that adiponectin is mainly affected by weight, not insulin.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>17204837</pmid><doi>10.1159/000098440</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1663-2818
ispartof Hormone research, 2007-01, Vol.68 (1), p.1-7
issn 1663-2818
1663-2826
1423-0046
language eng
recordid cdi_crossref_primary_10_1159_000098440
source Karger e-journals Complete Collection; MEDLINE; Alma/SFX Local Collection
subjects Adiponectin - blood
Child
Child, Preschool
Cholesterol - blood
Female
Ghrelin
Growth - drug effects
Human Growth Hormone - pharmacology
Human Growth Hormone - therapeutic use
Humans
Insulin Resistance
Leptin - blood
Original Paper
Peptide Hormones - blood
Peptide Hormones - drug effects
Triglycerides - blood
Turner Syndrome - blood
Turner Syndrome - drug therapy
Turner Syndrome - physiopathology
title Effects of Growth Hormone on Growth, Insulin Resistance and Related Hormones (Ghrelin, Leptin and Adiponectin) in Turner Syndrome
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T20%3A51%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20Growth%20Hormone%20on%20Growth,%20Insulin%20Resistance%20and%20Related%20Hormones%20(Ghrelin,%20Leptin%20and%20Adiponectin)%20in%20Turner%20Syndrome&rft.jtitle=Hormone%20research&rft.au=Darendeliler,%20Feyza&rft.date=2007-01-01&rft.volume=68&rft.issue=1&rft.spage=1&rft.epage=7&rft.pages=1-7&rft.issn=1663-2818&rft.eissn=1663-2826&rft_id=info:doi/10.1159/000098440&rft_dat=%3Cproquest_cross%3E2837639511%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1233233308&rft_id=info:pmid/17204837&rfr_iscdi=true